Giuseppe Banna: Deferred Nephrectomy after ICI in RCC May Enable Treatment De-Escalation
Giuseppe Banna, Head of Translational Research and Clinical Trials Unit of Thoracic Tumours at Candiolo Cancer Institute IRCCS and Consultant Medical Oncologist for Lung and Urology at Portsmouth Hospitals University NHS Trust, shared a post on X by The Oncologist, adding:
“Deferred cytoreductive nephrectomy after ICI in RCC is feasible. High rates of tumor necrosis, some pT0 responses, and >50% of patients able to discontinue systemic therapy suggest potential for treatment de-escalation.”
Quoting The Oncologist’s post about their paper by Paulo S do Amaral et al.:
“Deferred cytoreductive nephrectomy after ICI therapy in metastatic RCC shows promising results, with 67% of patients having a partial radiological response and 54% discontinuing systemic therapy. Extensive necrosis may be a key marker for durable responses.”
Title: Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors
Authors: Paulo S do Amaral, Kathryn E Beckermann, Jennifer B Gordetsky, Sam S Chang, Daniel D Joyce, Kerry Schaffer, Amy N Luckenbaugh, Morgan A Lambrecht, Elizabeth G Ryan, Daniel A Barocas, Kelvin A Moses, Brian I Rini
You can read the Full Article in The Oncologist.
More posts featuring Giuseppe Banna.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023